Cytokinetics Company Profile (NASDAQ:CYTK)

Analyst Ratings

Consensus Ratings for Cytokinetics (NASDAQ:CYTK) (?)
Ratings Breakdown: 6 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $19.00 (92.31% upside)

Analysts' Ratings History for Cytokinetics (NASDAQ:CYTK)
Show:
DateFirmActionRatingPrice TargetActions
7/13/2016FBR & CoReiterated RatingOutperform$24.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/12/2016Piper Jaffray Cos.Reiterated RatingOverweight$24.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/30/2016Roth CapitalReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/9/2016JPMorgan Chase & Co.Lower Price TargetMarket Outperform$16.00 -> $14.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/9/2016JMP SecuritiesLower Price TargetMarket Outperform$16.00 -> $14.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/17/2016Cowen and CompanyReiterated RatingBuy$16.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/24/2015MLV & Co.Reiterated RatingBuy$9.00 -> $14.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/26/2014 forward)

Earnings

Earnings History for Cytokinetics (NASDAQ:CYTK)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
7/28/2016ListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/28/2016Q1($0.37)($0.31)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/16/2016Q415($0.32)($0.24)$10.49 million$9.80 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/29/2015Q315($0.30)($0.23)$11.24 million$7.90 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/30/2015Q1($0.12)($0.23)$10.10 million$4.40 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/12/2015Q4($0.17)$0.23$10.80 million$21.80 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/30/2014Q3($0.27)($0.16)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/30/2014Q2($0.32)($0.23)$7.01 million$7.80 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/6/2014Q1($0.34)($0.27)$7.69 million$8.00 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/6/2014Q4($0.08)$0.21$19.14 million$24.30 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Cytokinetics (NASDAQ:CYTK)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.33)($0.33)($0.33)
Q2 20161($0.39)($0.39)($0.39)
Q3 20161($0.42)($0.42)($0.42)
Q4 20161($0.44)($0.44)($0.44)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Cytokinetics (NASDAQ:CYTK)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Cytokinetics (NASDAQ:CYTK)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
8/31/2015L Patrick GageDirectorBuy1,000$6.95$6,950.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/20/2015L Patrick GageDirectorBuy10,000$6.55$65,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/6/2015L Patrick GageDirectorBuy10,000$5.71$57,100.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/11/2015Andrew A WolffCMOSell21,875$7.80$170,625.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/30/2014Fady Ibraham MalikSVPSell21,630$6.73$145,569.90View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/9/2014L Patrick GageDirectorBuy10,850$4.09$44,376.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/25/2014Eastern Capital Ltdmajor shareholderBuy500,000$8.00$4,000,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Cytokinetics (NASDAQ:CYTK)
DateHeadline
07/25/16 02:48 PMBiotech Firms Fighting Cancer
07/24/16 03:21 PMCytokinetics Looking for Higher Pricing after ALS Drug is Approved - Equities.com
07/20/16 04:42 PMCytokinetics, Incorporated (NASDAQ:CYTK): Sell-Side Ratings and Company Earnings Glance - Engelwood Daily
07/20/16 08:52 AMCytokinetics (NASDAQ:CYTK) Sellers Increased By 10.66% Their Shorts - Consumer Eagle
07/18/16 03:39 PM5 Biotechnology Stocks to Buy Now - Investorplace.com
07/15/16 07:52 AMCytokinetics, Inc.'s Trend Down, Especially After Today's Weak Session - Consumer Eagle
07/14/16 03:18 PMCytokinetics to Announce Second Quarter Results on July 28, 2016 - [at noodls] - SOUTH SAN FRANCISCO, Calif., July 14, 2016 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq:CYTK) announced today that it is scheduled to report second quarter results on Thursday, July 28, 2016 at 4:00 ...
07/14/16 06:17 AMHow Analysts Feel About Cytokinetics, Inc. (NASDAQ:CYTK)? - Consumer Eagle
07/13/16 03:38 PMPiper Jaffray Analyst Bullish on Cytokinetics, Inc. (CYTK) - Smarter Analyst
07/12/16 07:52 AMCytokinetics (CYTK) Pipeline Progress to Be Seen in the 2nd-Half - Piper Jaffray - StreetInsider.com
07/12/16 07:52 AMCytokinetics (NASDAQ:CYTK) Sellers Covered 1.77% of Their Shorts - Press Telegraph
07/07/16 03:33 PMIs $24 Within Reach For Cytokinetics, Incorporated (NASDAQ:CYTK)? - Investor Newswire
07/06/16 03:36 PMPNM Resources, Inc. (NYSE:PNM) Fell -0.56%: Cytokinetics, Incorporated (NASDAQ:CYTK), Kearny Financial Corp ... - KC Register
07/06/16 03:36 PMBroker Outlook For Cytokinetics, Incorporated (NASDAQ:CYTK) - Fiscal Standard
07/06/16 03:36 PMCytokinetics to Present at Cantor Fitzgerald's 2nd Annual Healthcare Conference - GlobeNewswire (press release)
07/05/16 03:21 PMCytokinetics to Present at Cantor Fitzgerald’s 2nd Annual Healthcare Conference - [at noodls] - SOUTH SAN FRANCISCO, Calif., July 05, 2016 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq:CYTK) announced today that Robert I. Blum, President and Chief Executive Officer, is scheduled to present a corporate ...
07/04/16 03:20 PMBroker Outlook For The Week Ahead Cytokinetics, Incorporated (NASDAQ:CYTK) - Fiscal Standard
07/01/16 03:32 PMCytokinetics commences mid-stage study to assess effect of CK-2127107 on physical function in COPD patients - Seeking Alpha
07/01/16 03:32 PMAnalysts Dive Into Endo International plc – Ordinary Shares (ENDO) and Cytokinetics, Inc. (CYTK) With Different Views - Smarter Analyst
06/30/16 03:49 PMCytokinetics Announces Start of Phase 2 Clinical Trial of CK-2127107 in Patients With Chronic Obstructive Pulmonary Disease
06/30/16 09:04 AMCytokinetics (CYTK) Commences CK-107 Crossover Trial in COPD - StreetInsider.com
06/29/16 03:30 PMCytokinetics, Incorporated Stock Momentum Hits Strength - CML News
06/29/16 03:30 PMHow Analysts Feel About Cytokinetics, Inc. (NASDAQ:CYTK)? - Press Telegraph
06/28/16 08:25 AMCovering the Bases on Cytokinetics, Incorporated (NASDAQ:CYTK): Where is the Stock Going? - Press Telegraph
06/26/16 08:36 AMCytokinetics May/June Presentations Suggest High Likelihood Of Success - Seeking Alpha
06/26/16 08:36 AMCytokinetics (NASDAQ:CYTK) Shorts Decreased by 1.77% After Short Covering - Press Telegraph
06/19/16 07:59 AMWhat Analysts say about Cytokinetics, Inc. (NASDAQ:CYTK)? - iStreetWire
06/16/16 07:53 AMCytokinetics Incorporated (CYTK) Jumps 6.78% on June 15 - Equities.com
06/16/16 03:05 AMCytokinetics (CYTK) Looks Good: Stock Adds 6.8% in Session -
06/15/16 08:21 AMCytokinetics to Participate in Upcoming Investor Conferences - GlobeNewswire (press release)
06/14/16 03:09 PMCytokinetics to Participate in Upcoming Investor Conferences - [at noodls] - SOUTH SAN FRANCISCO, Calif., June 14, 2016 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq:CYTK) announced today that Robert I. Blum, President and Chief Executive Officer, is scheduled to present at the ...
06/09/16 10:49 AMCytokinetics, Incorporated (NASDAQ:CYTK) Fundamental Star Rating Report - CML News
06/01/16 03:45 PMHow Analysts Feel About Cytokinetics, Inc. (NASDAQ:CYTK)? - HNN - How Analysts Feel About Cytokinetics, Inc. (NASDAQ:CYTK)?HNNOut of 6 analysts covering Cytokinetics (NASDAQ:CYTK), 6 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Cytokinetics has been the topic of 5 analyst reports since July 24, 2015 according to StockzIntelligence Inc. Below is a ...Broker Watchlist: Cytokinetics, Incorporated (NASDAQ:CYTK)Share Trading Newsall 2 news articles »
05/27/16 12:54 PMAre Analysts Bearish Cytokinetics, Inc. (NASDAQ:CYTK) After Last Week? - Wall Street Hints and News - Are Analysts Bearish Cytokinetics, Inc. (NASDAQ:CYTK) After Last Week?Wall Street Hints and NewsOut of 6 analysts covering Cytokinetics (NASDAQ:CYTK), 6 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Cytokinetics has been the topic of 5 analyst reports since July 24, 2015 according to StockzIntelligence Inc. Below is a ...Cytokinetics, Incorporated (NASDAQ:CYTK) Closes At $8.21Investor NewswireCytokinetics, Incorporated (NASDAQ:CYTK) Stock Update & EstimatesStock Tick TockCytokinetics, Incorporated (NASDAQ:CYTK): Analysts Quick Take on EarningsNews Tribuneall 4 news articles »
05/24/16 12:20 PMBroker Outlook For Cytokinetics, Incorporated (NASDAQ:CYTK) - Share Trading News - Broker Outlook For Cytokinetics, Incorporated (NASDAQ:CYTK)Share Trading NewsBroker Outlook For Cytokinetics, Incorporated (NASDAQ:CYTK). By Brenton Akerman / in US Broker Ratings / on Tuesday, 24 May 2016 01:18 PM / 0 Comments. The most recently updated broker views and price targets issued for Cytokinetics, Incorporated ...and more »
05/23/16 01:57 PMCytokinetics (CYTK) Provides Additional COSMIC-HF Data; Improvement in LV Systolic Function Noted - StreetInsider.com - Cytokinetics (CYTK) Provides Additional COSMIC-HF Data; Improvement in LV Systolic Function NotedStreetInsider.comCytokinetics, Inc. (Nasdaq: CYTK) announced that additional results from COSMIC-HF (Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure), a Phase 2b trial evaluating omecamtiv mecarbil in patients with chronic heart ...Cytokinetics, Incorporated (NASDAQ:CYTK) - Broker UpdateRisers & FallersBroker Outlook For The Week Ahead Cytokinetics, Incorporated (NASDAQ:CYTK)Share Trading Newsall 3 news articles »
05/23/16 06:47 AMCYTOKINETICS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits -
05/23/16 06:46 AMCytokinetics Announces Presentation of Additional Results From COSMIC-HF at Heart Failure 2016 Congress - [at noodls] - Treatment with Omecamtiv Mecarbil Produced Progressive and Sustained Effects On Cardiac Function as Measured by Reductions in Diastolic Ventricular Volume and NT-proBNP SOUTH SAN FRANCISCO, Calif., May ...
05/22/16 01:15 PMCytokinetics (CYTK) Adds New Director - StreetInsider.com - Cytokinetics (CYTK) Adds New DirectorStreetInsider.comCytokinetics, Inc. (Nasdaq: CYTK) announced that Edward M. Kaye, M.D., has been appointed to the company's Board of Directors. Dr. Kaye is the Interim Chief Executive Officer and Senior Vice President, Chief Medical Officer of Sarepta Therapeutics.and more »
05/21/16 11:39 AMCytokinetics Appoints Edward M. Kaye, M.D., to Board of Directors - GlobeNewswire (press release) - Cytokinetics Appoints Edward M. Kaye, M.D., to Board of DirectorsGlobeNewswire (press release)SOUTH SAN FRANCISCO, Calif., May 20, 2016 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq:CYTK) announced today that Edward M. Kaye, M.D., has been appointed to the company's Board of Directors. Dr. Kaye is the Interim Chief Executive Officer ...and more »
05/20/16 03:35 PMCYTOKINETICS INC Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Submission of M -
05/20/16 03:33 PMCytokinetics Appoints Edward M. Kaye, M.D., to Board of Directors - [at noodls] - SOUTH SAN FRANCISCO, Calif., May 20, 2016 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq:CYTK) announced today that Edward M. Kaye, M.D., has been appointed to the company's Board of Directors. Dr. Kaye ...
05/19/16 11:41 AMHow Many Cytokinetics, Inc. (NASDAQ:CYTK)'s Analysts Are Bullish? - Wall Street Hints and News - How Many Cytokinetics, Inc. (NASDAQ:CYTK)'s Analysts Are Bullish?Wall Street Hints and NewsOut of 5 analysts covering Cytokinetics (NASDAQ:CYTK), 6 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Cytokinetics has been the topic of 5 analyst reports since July 24, 2015 according to StockzIntelligence Inc. Below is a ...Cytokinetics (NASDAQ:CYTK) Short Interest Decreased By 1.11%Franklin Independentall 3 news articles »
05/13/16 03:08 PMCytokinetics Announces Additional COSMIC-HF Results to Be Presented at Heart Failure 2016 - [at noodls] - SOUTH SAN FRANCISCO, Calif., May 13, 2016 (GLOBE NEWSWIRE) -- Cytokinetics, (Nasdaq:CYTK) announced today that a poster presentation on additional results from COSMIC-HF (Chronic Oral Study of Myosin Activation ...
05/11/16 04:07 PMCytokinetics to Hold Annual Meeting of Stockholders - [at noodls] - SOUTH SAN FRANCISCO, Calif., May 11, 2016 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq:CYTK) announced today that its Annual Meeting of Stockholders will be held on Wednesday, May 18, 2016 at 10:30 AM ...
05/05/16 04:04 PMCYTOKINETICS INC Files SEC form 10-Q, Quarterly Report -
05/02/16 06:30 AMCytokinetics to Ring Nasdaq Closing Bell to Launch ALS Awareness Month - [GlobeNewswire] - SOUTH SAN FRANCISCO, Calif., May 02, 2016-- Cytokinetics, Inc. today announced that it will ring the Closing Bell at Nasdaq this afternoon in recognition of ALS Awareness Month and the company’ s commitment ...
05/02/16 05:50 AMCytokinetics's (CYTK) CEO Robert Blum on Q1 2016 Results - Earnings Call Transcript - Seeking Alpha - Cytokinetics's (CYTK) CEO Robert Blum on Q1 2016 Results - Earnings Call TranscriptSeeking AlphaGood afternoon and welcome, ladies and gentlemen, to the Cytokinetics First Quarter 2016 conference call. At this time, I would like to inform you that this call is being recorded and that all participants are in a listen-only mode. [Operator ...The ALS Association and Cytokinetics Ring in May as ALS Awareness Month at NASDAQPR Newswire (press release)all 2 news articles »
04/30/16 05:58 AMRoth Capital Reiterates Buy on Cytokinetics, Inc. (CYTK) Following 1Q16 Update - Smarter Analyst - Web Breaking NewsRoth Capital Reiterates Buy on Cytokinetics, Inc. (CYTK) Following 1Q16 UpdateSmarter AnalystIn a research report published today, Roth Capital analyst Joseph Pantginis reiterated a Buy rating on shares of Cytokinetics Inc. (NASDAQ:CYTK), with a price target of $22, following the company's first-quarter results and update on its pipeline. The ...Cytokinetics, Inc. Reports First Quarter 2016 Financial ResultsGlobeNewswire (press release)Cytokinetics, Inc. (CYTK) Announces Quarterly Earnings Results, Beats Estimates By $0.06 EPSWeb Breaking NewsCytokinetics, Inc. (Nasdaq: CYTK) to Ring The Nasdaq Stock Market Closing BellEIN News (press release)B.O.D.Y Confidential -CWRU Observer -Share Trading Newsall 8 news articles »
04/29/16 03:14 PMEdited Transcript of CYTK earnings conference call or presentation 28-Apr-16 8:30pm GMT -

Social

About Cytokinetics

Cytokinetics logoCytokinetics, Incorporated is a biopharmaceutical company. The Company is focused on the discovery and development of small molecule therapeutics that modulate muscle function for the treatment of serious diseases and medical conditions. Its drug candidates include tirasemtiv, CK-2127107 and omecamtiv mecarbil. Its lead drug candidate from its skeletal muscle contractility program, tirasemtiv, is a skeletal muscle troponin activator. The Company is developing CK-2127107, a skeletal muscle troponin activator. The Company has conducted approximately five Phase I clinical trials of CK-2127107. Its lead drug candidate from its cardiac muscle contractility program, omecamtiv mecarbil, is a cardiac muscle myosin activator. COSMIC-HF is a Phase II, double-blind, randomized, placebo-controlled, multicenter, clinical trial designed to assess the pharmacokinetics and tolerability of omecamtiv mecarbil dosed orally in patients with heart failure and left ventricular systolic dysfunction.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: CYTK
  • CUSIP:
Key Metrics:
  • Previous Close: $9.88
  • 50 Day Moving Average: $9.30
  • 200 Day Moving Average: $7.95
  • P/E Ratio: N/A
  • P/E Growth: -0.44
  • Market Cap: $391.46M
  • Beta: 1.29
  • Current Year EPS Consensus Estimate: $-1.46 EPS
  • Next Year EPS Consensus Estimate: $-1.89 EPS
Additional Links:
Cytokinetics (NASDAQ:CYTK) Chart for Tuesday, July, 26, 2016